Clinical Trial News and Research

RSS

Results from ongoing clinical trial of ISF35 to be presented at ASH annual meeting

Memgen announced today that results from its ongoing, Leukemia & Lymphoma Society co-sponsored clinical trial in chronic lymphocytic leukemia (CLL) have been selected for an oral presentation at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana.

2 Dec 2009

Annual screening ultrasound may benefit women who are at elevated risk for breast cancer

Results of a large-scale clinical trial presented today at the annual meeting of the Radiological Society of North America (RSNA) provide the first strong evidence of the benefit of annual screening ultrasound for women with dense breasts who are at elevated risk for breast cancer. In addition, the study confirmed that MRI is highly sensitive in depicting early breast cancer.

2 Dec 2009

Ohr Pharmaceutical to present interim data from ongoing Phase II clinical trial of OHR/AVR118

Ohr Pharmaceutical Inc., announced that interim data from the company's ongoing Phase II clinical trial of OHR/AVR118 for the treatment of Cachexia, will be presented at the 5th annual meeting of the Society on Cachexia and Wasting Disorders (SCWD), which will be held in Barcelona December 5 - December 8, 2009.

2 Dec 2009

CRO to run CEL-SCI's upcoming Phase III clinical trial

CEL-SCI Corporation, a late-stage oncology company and a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases, announced today that it has retained the services of an international Contract Research Organization (CRO) to run CEL-SCI's upcoming Phase III clinical trial in advanced primary head and neck cancer with the Company's lead product candidate, Multikine®.

1 Dec 2009

Positive data from Provectus Pharmaceuticals' psoriasis and atopic dermatitis trials

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced preliminary data for the company’s PH-10 Phase 2 clinical trial for Psoriasis as well as for its Phase 2 clinical trial for Atopic Dermatitis.

1 Dec 2009

StemCyte concludes exclusive license and commercialization agreement with Academia Sinica

StemCyte, Inc. concluded an exclusive license and commercialization agreement with Academia Sinica, the National Laboratory of Taiwan, for certain proprietary methods and Intellectual Property (IP) related to the treatment of Chronic Stroke with stem cells.

1 Dec 2009

Clinical trail shows PAD patients also experience asymptomatic heart disease

Results of a randomized, controlled clinical trial presented today at the annual meeting of the Radiological Society of North America (RSNA) reveal that one in five patients with narrowing or blockage in arteries that supply blood to the legs and other parts of the body also have significant but silent coronary artery disease.

1 Dec 2009

Phase 1 study of preventive HIV vaccine testing a novel delivery mechanism completed

A Phase 1 study of a preventive HIV vaccine testing a novel delivery mechanism known as electroporation – the use of electrical pulses to increase the immune responses elicited by DNA vaccines – was recently completed in New York City.

1 Dec 2009

Tripep completes phase I clinical study of its ChronVac-C hepatitis C virus DNA vaccine

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that its partner Tripep AB of Sweden has completed its phase I clinical study of its ChronVac-C hepatitis C virus DNA vaccine delivered using Inovio’s electroporation technology.

30 Nov 2009

Bayer Healthcare Pharmaceuticals commences enrollment in florbetaben Phase III clinical trials

Today at the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Bayer HealthCare Pharmaceuticals Inc. announced the enrollment of the first patient in an international Phase III clinical trial to evaluate the efficacy and safety of florbetaben (BAY 94-9172) PET imaging in the detection of beta-Amyloid plaques in the brain, which are a pathological hallmark of Alzheimer's disease.

30 Nov 2009

NOVAVAX completes patient enrollment in its trivalent seasonal influenza VLP vaccine Phase II study

Novavax, Inc. announced today it has completed enrollment in the Phase II clinical study of its trivalent seasonal influenza (2008/2009 recommended strains) VLP vaccine candidate in healthy adults 60 years of age or older (older adults). This randomized, double-blind, active-controlled study is comparing the safety, tolerability and immunogenicity of two different doses (15 mcg and 60 mcg) of Novavax's trivalent seasonal influenza VLP vaccine to a commercially available trivalent inactivated vaccine, TIV (Fluzone®).

30 Nov 2009

MagForce Nanotechnologies initiates conformity assessment procedure for its Nano-Cancer therapy

MagForce Nanotechnologies AG has submitted the product file for NanoTherm® to Medcert GmbH, the medical certification and testing company which serves as Notified Body for the certification of medical products. With this step, MagForce has now commenced the conformity assessment procedure for its Nano-Cancer ® therapy.

30 Nov 2009

Kiadis Pharma commences enrollment in multinational ATIR study

Biopharmaceutical company Kiadis Pharma announces today that the first patients have been enrolled in its multinational registration clinical trial with ATIR(TM). The study is designed to show reduction in transplant related mortality (TRM) after one year following an allogeneic stem cell transplantation with a mismatched (haplo-identical) donor in blood cancer patients eligible for an allogeneic stem cell transplantation but without having a matched donor available.

30 Nov 2009

Micromet to present new results from its blinatumomab study at the ASH meeting

Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will present new results from its clinical studies with blinatumomab at the 51st annual meeting of the American Society of Hematology from December 5-8, 2009 in New Orleans, Louisiana.

30 Nov 2009

Spectrum Pharmaceuticals completes enrollment in apaziquone Phase 3 trial

Spectrum Pharmaceuticals today announced that one of the two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target, having enrolled approximately 800 patients with non-invasive bladder cancer. The second Phase 3 clinical trial of apaziquone is expected to complete enrollment by the end of the year.

30 Nov 2009

Gentium announces financial results for the third quarter ended September 30, 2009

Gentium S.p.A. today reported financial results for the quarter ended September 30, 2009.

30 Nov 2009

$Stem cell technology for rapid healing of complicated bone fractures$

Stem cell technology for rapid healing of complicated bone fractures

A novel technology involving use of stem cells, developed by Hebrew University of Jerusalem researchers, has been applied to provide better and rapid healing for patients suffering from complicated bone fractures.

30 Nov 2009

Intellivest Securities Research publishes a Report on BioClinica

Intellivest Securities Research, Inc., ("ISR") a Georgia registered investment advisor, has published a Report on BioClinica, Inc. ( BIOC) which serves companies in the pharmaceutical, biotechnology and medical device industries.

30 Nov 2009

Tripep completes clinical trial of ChronVac-C for Hepatitis C virus treatment

All samples from the 12 patients with chronic Hepatitis C genotype 1 treated with Tripep’s therapeutic vaccine ChronVac-C have now been collected. The treatment was found to be safe, immunogenic and had transient effects on the serum levels of hepatitis C virus.

27 Nov 2009

European Commission approves MICARDIS medication for CV protection

MICARDIS® is the first treatment in its class to be approved for this indication. The EMEA approval is the second major milestone for MICARDIS® in cardiovascular protection. It follows the approval by the US FDA for the reduction of the risk of myocardial infarction (heart attack), stroke, or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors.

27 Nov 2009

Clinical Trial News and Research

Results from ongoing clinical trial of ISF35 to be presented at ASH annual meeting

Annual screening ultrasound may benefit women who are at elevated risk for breast cancer

Ohr Pharmaceutical to present interim data from ongoing Phase II clinical trial of OHR/AVR118

CRO to run CEL-SCI's upcoming Phase III clinical trial

Positive data from Provectus Pharmaceuticals' psoriasis and atopic dermatitis trials

StemCyte concludes exclusive license and commercialization agreement with Academia Sinica

Clinical trail shows PAD patients also experience asymptomatic heart disease

Phase 1 study of preventive HIV vaccine testing a novel delivery mechanism completed

Tripep completes phase I clinical study of its ChronVac-C hepatitis C virus DNA vaccine

Bayer Healthcare Pharmaceuticals commences enrollment in florbetaben Phase III clinical trials

NOVAVAX completes patient enrollment in its trivalent seasonal influenza VLP vaccine Phase II study

MagForce Nanotechnologies initiates conformity assessment procedure for its Nano-Cancer therapy

Kiadis Pharma commences enrollment in multinational ATIR study

Micromet to present new results from its blinatumomab study at the ASH meeting

Spectrum Pharmaceuticals completes enrollment in apaziquone Phase 3 trial

Gentium announces financial results for the third quarter ended September 30, 2009

Stem cell technology for rapid healing of complicated bone fractures

Intellivest Securities Research publishes a Report on BioClinica

Tripep completes clinical trial of ChronVac-C for Hepatitis C virus treatment

European Commission approves MICARDIS medication for CV protection

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News